Authored by James Sheppard
The New York based biopharmaceutical company Loxo Oncology announced that it had added several senior executives across the company to help the company expand and build the clinical pipeline and advance early drug development.
The appointments have come across a range of functions including: Dr Dov Goldstein as Chief Financial Officer (CFO) and board member, Dr Jennifer Low as Executive Vice President of Research & Development and Mr Jacob Van Naarden as Vice President of Corporate Development & Strategy.
Dr Goldstein is an operating partner at Aisling Capital and was most recently Partner at Aisling Capital. Previous to this, Dr Goldstein served as Executive Vice President and CFO of Vicuron Pharmaceuticals, where he helped lead Vicuron through on IPO and subsequent acquisition by Pfizer. Mr Van Naarden who was also previously an associate at Aisling Capital joins from his most recent position as a biotechnology equity analyst at HealthCor Management. Dr Low was previously Senior Group Medical Director at Genentech where she led the development of Erivedge and a number of other key assets.